论文部分内容阅读
培哚普利(Perindopril)是一种新的长效无巯基ACE抑制剂。本文采用多中心、双盲试验比较了本品与阿替洛尔对轻、中度原发性高血压的降压效果和安全性。研究对象为190例轻、中度原发性高血压病人,卧位舒张压为12.6~15.3 kPa,其中49例有糖尿病。所有病人在2~4周的安慰剂治疗后被随机分为本品组(94例)和阿替洛尔组(96例)。本品和阿替洛尔的起始量为2mg和25mg每日1次。若给药过程中卧位舒张压大于11.9kPa,则剂量逐渐加倍至最大剂量(8mg和100mg每日1次);
Perindopril is a new long-acting, mercapto-free ACE inhibitor. In this paper, a multicenter, double-blind trial of this product and atenolol on mild to moderate essential hypertension antihypertensive effect and safety. The object of study was 190 patients with mild to moderate essential hypertension. The diastolic blood pressure in the supine position was 12.6-15.3 kPa, of which 49 cases had diabetes mellitus. All patients were randomized to receive this product (n = 94) and atenolol (n = 96) after 2 to 4 weeks of placebo treatment. This product and atenolol starting amount of 2mg and 25mg daily 1. If the diastolic blood pressure during treatment is greater than 11.9kPa, the dose is gradually doubled to the maximum dose (8mg and 100mg daily);